Literature DB >> 31493201

Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Dario Camellino1,2, Andrea Giusti3, Giuseppe Girasole3, Gerolamo Bianchi3, Christian Dejaco4,5.   

Abstract

Polymyalgia rheumatica is an inflammatory rheumatic disease of the elderly characterised by pain and stiffness in the neck and pelvic girdle, and is the second most common inflammatory rheumatic condition in this age group, after rheumatoid arthritis. Polymyalgia rheumatica can occur independently or in association with giant cell arteritis, which is the most common form of primary vasculitis. The diagnosis of polymyalgia rheumatica is usually based on clinical presentation and increase of inflammatory markers. There are no pathognomonic findings that can confirm the diagnosis. However, different imaging techniques, especially ultrasonography, can assist in the identification of polymyalgia rheumatica. Glucocorticoids are the cornerstone of the treatment of polymyalgia rheumatica, but they might be associated with different adverse events. A subgroup of patients presents with a refractory disease course and, in these cases, adding methotrexate as a steroid-sparing agent could be useful. In this review, we summarise the latest findings regarding the pathogenesis, diagnosis and management of polymyalgia rheumatica and try to highlight the possible pitfalls, especially in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31493201     DOI: 10.1007/s40266-019-00705-5

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  116 in total

1.  Clinical images: the multifaceted pathogenesis of polymyalgia rheumatica/giant cell arteritis.

Authors:  Dario Camellino; Gianmario Sambuceti; Silvia Morbelli; Marco A Cimmino
Journal:  Arthritis Rheum       Date:  2009-09

2.  Is FDG-PET useful in the evaluation of steroid-resistant PMR patients?

Authors:  M A Cimmino; G Zampogna; M Parodi
Journal:  Rheumatology (Oxford)       Date:  2008-04-04       Impact factor: 7.580

3.  Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.

Authors:  Izzat Shbeeb; Divya Challah; Shafay Raheel; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

4.  Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype.

Authors:  M Fallah; X Liu; J Ji; A Försti; K Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

5.  Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis.

Authors:  Soren Jacobsen; Bo Baslund; Hans Ole Madsen; Niels Tvede; Arne Svejgaard; Peter Garred
Journal:  J Rheumatol       Date:  2002-10       Impact factor: 4.666

6.  Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica.

Authors:  N T Baerlecken; A Linnemann; W L Gross; F Moosig; T R Vazquez-Rodriguez; M A Gonzalez-Gay; J Martin; I Kötter; J C Henes; I Melchers; P Vaith; R E Schmidt; T Witte
Journal:  Ann Rheum Dis       Date:  2012-01-05       Impact factor: 19.103

7.  A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury.

Authors:  Rita Simone; Renata Brizzolara; Alessandra Chiappori; Francesca Milintenda-Floriani; Clelia Natale; Luigi Greco; Mara Schiavo; Marcello Bagnasco; Giampaola Pesce; Daniele Saverino
Journal:  Int Immunol       Date:  2009-07-22       Impact factor: 4.823

8.  Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in a Patient After Treatment With Nivolumab.

Authors:  Albrecht Edward Betrains; Daniel Engelbert Blockmans
Journal:  J Clin Rheumatol       Date:  2021-12-01       Impact factor: 3.517

9.  The soluble isoform of CTLA-4 as a regulator of T-cell responses.

Authors:  Frank J Ward; Lekh N Dahal; Subadra K Wijesekera; Sultan K Abdul-Jawad; Taniya Kaewarpai; Heping Xu; Mark A Vickers; Robert N Barker
Journal:  Eur J Immunol       Date:  2013-03-06       Impact factor: 5.532

Review 10.  The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome.

Authors:  S Muller; S Hider; T Helliwell; R Partington; C Mallen
Journal:  Reumatismo       Date:  2018-03-27
View more
  12 in total

Review 1.  Polymyalgia Rheumatica.

Authors:  Miriam Giovanna Colombo; Anna-Jasmin Wetzel; Hannah Haumann; Simon Dally; Gudula Kirtschig; Stefanie Joos
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

Review 2.  Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: working notes from a narrative review of published literature.

Authors:  Ciro Manzo; Alberto Castagna; Marco Isetta
Journal:  Reumatologia       Date:  2022-05-18

3.  Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination.

Authors:  Azam Safary; Kamal Esalatmanesh; Amir Taher Eftekharsadat; Mohammad-Reza Jafari Nakjavani; Alireza Khabbazi
Journal:  Int Immunopharmacol       Date:  2022-07-15       Impact factor: 5.714

Review 4.  Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides.

Authors:  Enrico Tombetti; Elvis Hysa; Justin C Mason; Marco A Cimmino; Dario Camellino
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

Review 5.  The Immunopathology of Giant Cell Arteritis Across Disease Spectra.

Authors:  Michelle L Robinette; Deepak A Rao; Paul A Monach
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

6.  Depression and depressive symptoms in patients with polymyalgia rheumatica: discussion points, grey areas and unmet needs emerging from a systematic review of published literature.

Authors:  Ciro Manzo; Ayar Nizama-Via; Marcin Milchert; Marco Isetta; Alberto Castagna; Maria Natale; Jordi Serra-Mestres
Journal:  Reumatologia       Date:  2020-12-23

Review 7.  Feasibility and usefulness of a fast-track clinic for patients suspected of polymyalgia rheumatica: notes for a work schedule through a narrative review of published literature.

Authors:  Elvis Hysa; Ali Ghorbannia; Amir Emamifar; Marcin Milchert; Ciro Manzo
Journal:  Reumatologia       Date:  2021-11-07

Review 8.  Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases.

Authors:  Kalliopi Klavdianou; Konstantinos Melissaropoulos; Alexandra Filippopoulou; Dimitrios Daoussis
Journal:  Mediterr J Rheumatol       Date:  2021-09-30

9.  The Combination of 18F-Fluorodeoxyglucose Positron Emission Tomography Metabolic and Clinical Parameters Can Effectively Distinguish Rheumatoid Arthritis and Polymyalgia Rheumatic.

Authors:  Guanyun Wang; Xiaofei Liu; Jiaxin Chen; Fengyan Zhang; Xiaodan Xu; Yanmei Wang; Ruimin Wang; Shulin Yao; Jian Zhu; Zhiwei Guan
Journal:  Contrast Media Mol Imaging       Date:  2022-04-11       Impact factor: 3.009

10.  The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.

Authors:  Ciro Manzo; Elvis Hysa; Alberto Castagna; Marco Isetta
Journal:  J Pers Med       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.